A quick survey shows that most small and mid-sized Fine Chemical companies are performing well even under the more difficult circumstances of Covid-19. Many of them are even investing to increase capacity and add new technologies, moreover, acquisitions are ongoing. Some examples: Hikal is investing US$ 50 Mio. fo capacity increase and new technologies, Flamma is building a new R&D Center in Italy, Dipharma has added a cGMP kilolab at Dipharma-Kalexsyn USA. Financial performance is good.